Glaukos Co. (NYSE:GKOS) Shares Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board increased its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 5.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,605 shares of the medical instruments supplier's stock after buying an additional 5,700 shares during the period. Public Sector Pension Investment Board owned about 0.21% of Glaukos worth $15,191,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new position in Glaukos during the second quarter worth $6,832,000. WCM Investment Management LLC increased its position in Glaukos by 45.7% during the 3rd quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier's stock worth $12,721,000 after purchasing an additional 31,084 shares in the last quarter. First Turn Management LLC acquired a new position in Glaukos in the 3rd quarter valued at about $12,520,000. Victory Capital Management Inc. raised its stake in Glaukos by 421.8% in the 3rd quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier's stock valued at $10,320,000 after purchasing an additional 64,031 shares during the last quarter. Finally, Seven Eight Capital LP purchased a new position in Glaukos in the 2nd quarter valued at about $1,940,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company's stock, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Glaukos Trading Up 0.8 %

GKOS stock traded up $1.12 during midday trading on Friday, reaching $143.81. 165,871 shares of the company's stock traded hands, compared to its average volume of 570,121. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a fifty-two week low of $59.58 and a fifty-two week high of $146.86. The business has a 50-day moving average price of $133.81 and a two-hundred day moving average price of $124.52. The company has a market capitalization of $7.93 billion, a P/E ratio of -47.25 and a beta of 1.02.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same period last year, the company posted ($0.50) earnings per share. The firm's revenue was up 23.9% compared to the same quarter last year. Equities research analysts forecast that Glaukos Co. will post -1.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Glaukos from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Stifel Nicolaus boosted their price target on Glaukos from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. StockNews.com upgraded Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. Truist Financial lifted their price objective on Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Finally, BTIG Research increased their target price on Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $135.45.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.